An “onco score” is a shorthand term for the Oncotype DX Recurrence Score, a number between 0 and 100 that predicts how likely certain cancers are to come back after surgery. The test is most commonly used for early-stage breast cancer, where it analyzes the activity of 21 genes inside a tumor sample to estimate recurrence risk and, critically, whether chemotherapy would provide a meaningful benefit. A version of the test also exists for stage 2 colon cancer, using 12 genes instead of 21.
If your doctor mentioned an “onco score,” they’re almost certainly talking about this test. Here’s what the number means and how it shapes treatment decisions.
How the Test Works
The Oncotype DX test is performed on tumor tissue that was already removed during a biopsy or surgery. No additional procedure is needed. A lab examines the activity levels of a specific panel of genes within that tissue, then uses those measurements to calculate a single recurrence score. For breast cancer, 21 genes are analyzed. For colon cancer, 12 genes (7 cancer-related and 5 reference genes) are measured.
The score reflects the individual biology of your tumor, not just its size or how it looks under a microscope. Two tumors that appear identical on a pathology report can behave very differently at the genetic level, and the recurrence score captures that difference.
What the Score Ranges Mean
For breast cancer, the recurrence score falls on a scale from 0 to 100. A score of 25 or lower is considered low risk. A score of 26 or higher is considered high risk. The higher the number, the greater the estimated chance of the cancer returning.
For colon cancer, the scale is also 0 to 100 but the cutoffs differ. A score below 30 is low risk, 30 to 40 is intermediate, and 41 or above is high risk.
These numbers aren’t abstract. They directly influence whether your oncologist recommends chemotherapy on top of other treatments, or whether you can safely skip it.
Who Gets the Test
Not every breast cancer patient is a candidate. The test is designed for a specific profile: estrogen receptor-positive, HER2-negative invasive breast cancer with a tumor larger than 5 millimeters. For premenopausal women, the cancer generally needs to have no lymph node spread (or only microscopic amounts). For postmenopausal women, the test can also be used when up to three nearby lymph nodes are involved.
The National Comprehensive Cancer Network gives the test its strongest recommendation (category 1) for node-negative patients with tumors over 0.5 cm, meaning the evidence behind it is considered robust and widely accepted. If your tumor is hormone receptor-negative or HER2-positive, different treatment strategies apply and this particular test won’t be ordered.
How It Changes Treatment Decisions
The most important thing the recurrence score does is answer a question that used to be guesswork: will chemotherapy actually help you? For many women with early-stage breast cancer, the answer turns out to be no.
The landmark TAILORx trial enrolled thousands of women with intermediate recurrence scores (11 to 25) and randomly assigned them to either hormone therapy alone or hormone therapy plus chemotherapy. The results were striking. At five years, 92.8% of women on hormone therapy alone were free of invasive disease, compared to 93.1% of those who also received chemotherapy. At nine years, the numbers were 83.3% and 84.3%, respectively. The differences were not statistically significant, meaning chemotherapy added no measurable benefit for most women in this range.
That finding spares thousands of patients each year from months of chemotherapy, along with its side effects, costs, and disruption to daily life. For women with high scores (26 and above), the data supports a clearer benefit from adding chemotherapy, making the decision more straightforward in the other direction.
Age Matters for Interpretation
One important nuance: the score doesn’t mean the same thing for every age group. The TAILORx trial found that premenopausal women and those under 50 with scores in the higher end of the intermediate range (16 to 25) may still get a small benefit from chemotherapy. For women over 50 with the same scores, there was no meaningful advantage.
This distinction matters because younger women’s breast cancers tend to behave more aggressively, and the hormonal environment before menopause plays a role. If you’re under 50 with a score between 16 and 25, your oncologist will likely discuss chemotherapy as a real consideration rather than something to skip. If you’re over 50 with the same score, the conversation will lean toward hormone therapy alone.
For older adults, the interpretation gets more layered still. Hormone receptor-positive tumors become more common with age, but the risk of recurrence relative to other health concerns decreases. A 75-year-old with a moderate score faces different trade-offs than a 45-year-old with the same number.
The Colon Cancer Version
The 12-gene Oncotype DX Colon Recurrence Score works on a similar principle but for a different clinical question. It’s validated for stage 2 colon cancer after surgical removal, helping estimate recurrence risk based on individual tumor biology rather than relying solely on tumor stage or other broad markers. Data from over 20,000 stage 2 patients has been used to validate the test.
The score provides a more individualized risk picture than staging alone. A patient with a low colon recurrence score might reasonably forgo adjuvant chemotherapy, while a high score could justify the added treatment. The goal is the same as in breast cancer: matching treatment intensity to actual biological risk.
Insurance and Access
Medicare covers the Oncotype DX test when specific clinical criteria are met, including the tumor characteristics described above and the requirement that the result will genuinely influence the treatment plan. Private insurers generally follow similar guidelines, though the specifics of coverage can vary by plan. If you meet the standard eligibility criteria, coverage is likely, but confirming with your insurer before the test is ordered can prevent surprises.
Results typically come back within one to two weeks after the lab receives the tissue sample. Your oncologist will walk through the score with you, usually alongside other pathology findings, to build a complete treatment recommendation.